Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Papers 1: Immunotherapy

1O - Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)


02 Mar 2020


Proffered Papers 1: Immunotherapy


Christophe Le Tourneau


Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86


C. Le Tourneau1, D. Rischin2, S. Groenland3, A. Lim4, J. Martin-Liberal5, V. Moreno6, J.M. Trigo7, M. Mathew8, D. Cho9, A. Hansen10, D. Vincente Baz11, M. Maio12, A. Italiano13, J. Bauman14, M. Chisamore15, H. Zhou16, C. Ellis16, M. Ballas16, A. Hoos16, E. Angevin17

Author affiliations

  • 1 Institut Curie, 75248 - Paris/FR
  • 2 Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne/AU
  • 3 Antoni Van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam/NL
  • 4 Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands/AU
  • 5 Vall d’Hebron Institute of Oncology (VHIO)-Cellex Cente, Barcelona/ES
  • 6 START Madrid-FJD, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 7 Hospital Universitario Virgen de la Victoria, Málaga/ES
  • 8 Columbia University Medical Center, New York/US
  • 9 New York University Langone Medical Center, New York/US
  • 10 Princess Margaret Cancer Center, Toronto/CA
  • 11 Hospital Universitario Virgen Macarena, Sevilla/ES
  • 12 University Hospital of Siena, Siena/IT
  • 13 Institut Bergonié, Bordeaux/FR
  • 14 Fox Chase Cancer Center, Philadelphia/US
  • 15 Merck & Co., Inc, North Wales/US
  • 16 GSK, Collegeville/US
  • 17 Gustave Roussy Institut de Cancérologie, Villejuif/FR


Abstract 1O

INDUCE-1 is a first-in-human study investigating GSK609 alone (mono) and in combination (combo) with other regimens including pembrolizumab (pembro). The study consists of dose escalation (DE) and expansion phases. Findings from DE and PK/PD mono cohorts demonstrated that a range of GSK609 doses (≥0.1-1 mg/kg) have biological and clinical activity supporting the mechanism of action of a non-T cell depleting IgG4 ICOS agonist antibody as a clinical target.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings